Qube Research & Technologies (QRT)
MLTX icon

Qube Research & Technologies (QRT)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.66M Buy
496,242
+453,325
+1,056% +$8.22M 0.01% 1308
2026
Q1 		$800K Buy
+42,917
New +$711K ﹤0.01% 2580
2024
Q2 		– Sell
-5,655
Closed -$284K – 4399
2024
Q1 		$284K Sell
5,655
-13,265
-70% -$720K ﹤0.01% 2846
2023
Q4 		$1.14M Buy
+18,920
New +$975K ﹤0.01% 1848

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Qube Research & Technologies (QRT)'s MLTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) increased its MoonLake Immunotherapeutics (MLTX) stake by 1,056% in Q2 2026, buying an estimated $8.22M and bringing the position to 496,242 shares worth $9.66M. The position accounts for 0.01% of the portfolio, ranked #1308.

Qube Research & Technologies (QRT) first reported a position in MLTX in Q4 2023 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 496,242 shares of MoonLake Immunotherapeutics worth $9.66M as of Q2 2026.
  • Qube Research & Technologies (QRT) bought 453,325 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $8.22M.
  • MoonLake Immunotherapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1308 holding.
  • Qube Research & Technologies (QRT) first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.